Shares in Emergent BioSolutions Inc. (EBS) dropped 14% in Friday’s after-hours trading following the disclosure of two of its directors divesting shares.
According to a SEC filing, Emergent Director Ronald Richard sold 6,572 shares on Wednesday at an average price of $87.514, for a total of about $575,142. Following the share sale Richard owns 4,269 shares. The stock rose 2.5% to $86.91 on Friday before dropping to $75 in post-market trading.
In addition, Director Sue Bailey divested 5,322 shares at an average price of $87.503, generating about $465,691 from the sale. Bailey now still has 37,260 shares in the company.
Earlier this month, Emergent BioSolutions announced that it is joining the U.S. government’s warp speed program in a public-private partnership for COVID-19 vaccine development and production. The task order valued at about $628 million is for rapid domestic manufacturing of leading COVID-19 vaccine candidates through 2021. The global life sciences company will provide molecule-to-market contract development and manufacturing (CDMO) services and commit to manufacturing capacity, valued at about $542.7 million.
Shares in Emergent have this year already soared 61%. Despite the rally, Guggenheim analyst Dana Flanders still sees room for more gains ahead.
Following the task order, Flanders last week raised the stock’s price target to $101 (16% upside potential) from $81 and keept a Buy rating.
This “landmark” partnership is “tangible evidence” of Emergent’s contract development and manufacturing organization and capability, Flanders wrote in a note to investors, adding that he believes that the CDMO business opportunity is growing and durable.
Overall, the stock boasts 4 Buy ratings versus 1 Hold rating adding up to a Strong Buy consensus. Meanwhile, the $88 average analyst price target sees little upside potential for the shares in the next 12 months. (See EBS stock analysis on TipRanks).
Teva Wins Court Ruling Against Opiant, Emergent Bio On Narcan Nasal Spray
5 Promising Covid-19 Vaccines Picked For Trump’s Operation Warp Speed
Think Novavax Has Surged Enough for Now? Think Again, Says 5-Star Analyst